Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short

view original post

Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.